Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol and melitracen is a fixed-dose combination of a thioxanthene antipsychotic and a tricyclic antidepressant, respectively. It is used for the treatment of depression and anxiety.
## Primary Indications
* Depression
* Anxiety
* Mixed anxiety and depression
## Adult Dosing
* **Starting dose:** 1 tablet (flupentixol 0.5 mg, melitracen 10 mg) twice daily.
* **Maintenance dose:** 1-2 tablets twice daily.
* **Maximum dose:** 2 tablets twice daily, or 4 tablets total per day.
* Dosing should be individualized based on patient response and tolerability. Exact dosing can depend on local protocols.
## Pediatric Dosing
* Safety and efficacy in pediatric patients have not been established. Use is not recommended.
## Dose Adjustments
* **Renal impairment:** No specific dose adjustments are typically recommended, but caution and close monitoring are advised due to potential accumulation.
* **Hepatic impairment:** Caution is advised. Dose reduction may be necessary, and close monitoring of liver function and adverse effects is recommended.
## Contraindications
* Known hypersensitivity to flupentixol, melitracen, or any component of the formulation.
* Acute excitement or psychomotor agitation.
* Circulatory collapse.
* Marked CNS depression.
* Blood dyscrasias.
* Untreated narrow-angle glaucoma.
* Phacochromocytoma.
* Concurrent use with MAO inhibitors or within 14 days of discontinuing MAO inhibitors.
## Adverse Effects
* **Common:** Sedation, somnolence, dry mouth, constipation, blurred vision, dizziness, headache, fatigue, tremor, insomnia, nausea, sweating.
* **Less common/Serious:** Extrapyramidal symptoms (akathisia, dystonia, parkinsonism – more associated with flupentixol), anticholinergic effects (urinary retention, tachycardia), hypotension, arrhythmias, ECG changes, sexual dysfunction, weight gain, hyponatremia, increased risk of suicidal thoughts and behavior (especially in younger adults).
## Key Drug Interactions
* **MAO Inhibitors:** Increased risk of hypertensive crisis and serotonin syndrome. Avoid concurrent use.
* **CNS Depressants (e.g., alcohol, benzodiazepines, opioids):** Additive sedative effects.
* **Anticholinergic Agents:** Increased risk of anticholinergic side effects.
* **Drugs affecting QT interval:** Increased risk of QTc prolongation and arrhythmias.
* **CYP2D6 Inhibitors:** May increase flupentixol and melitracen plasma concentrations.
## Monitoring
* Mental status and mood changes, including suicidal ideation.
* Signs and symptoms of extrapyramidal side effects.
* Anticholinergic side effects.
* Cardiovascular status (blood pressure, heart rate, ECG if indicated).
* Liver function tests may be considered in patients with hepatic impairment or prolonged therapy.
* Electrolyte levels (e.g., sodium) if clinically indicated.
## Clinical Pearls
* This combination is often initiated at lower doses and titrated upwards to minimize sedation and other side effects.
* Therapeutic effects may take several weeks to become apparent.
* Discontinuation should be gradual to avoid withdrawal symptoms.
* Use with caution in patients with cardiovascular disease, seizure disorders, or a history of urinary retention.
* Due to the potential for sedation, patients should be advised to avoid operating machinery or driving until they know how the medication affects them.
***
**Disclaimer:** This information is intended for clinical decision support and does not replace professional medical judgment. It is essential to consult the most current prescribing information and local guidelines before making treatment decisions.
